Compare MBAI & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | CURX |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 9.4M |
| IPO Year | 2014 | 2024 |
| Metric | MBAI | CURX |
|---|---|---|
| Price | $6.30 | $5.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.4K | ★ 135.8K |
| Earning Date | 05-12-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.18 |
| 52 Week High | $10.21 | $9.18 |
| Indicator | MBAI | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 82.50 |
| Support Level | $1.19 | $0.33 |
| Resistance Level | $10.21 | $6.00 |
| Average True Range (ATR) | 0.37 | 0.57 |
| MACD | -0.31 | 0.09 |
| Stochastic Oscillator | 11.04 | 76.09 |
MBody AI Ltd is an embodied artificial intelligence company. Its core technology is the MBody AI Orchestrator (Orchestrator), a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively. MBody AI does not manufacture robots; it makes third-party robots more intelligent and coordinated through the Orchestrator and deploys them at customer sites together with its software and related services. Each deployment is designed to generate proprietary operational data. Its initial commercial focus is the hospitality industry, with potential applications across other labor-intensive sectors, including warehousing, office management, and healthcare.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.